2017
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer. American Journal Of Clinical Oncology 2017, 40: 393-398. PMID: 26986978, PMCID: PMC5026539, DOI: 10.1097/coc.0000000000000171.Peer-Reviewed Original ResearchConceptsGastroesophageal junction carcinomaPreoperative chemoradiationPreoperative chemotherapyAdditional patientsSmall molecule receptor tyrosine kinase inhibitorGrade 4 nonhematologic toxicityReceptor tyrosine kinase inhibitorsPhase ICommon acute toxicitiesLocalized esophageal cancerResectable esophagogastric cancerTolerability of vandetanibMedian overall survivalMicroscopic residual diseasePathologic complete responseLocalized esophageal carcinomaTyrosine kinase inhibitorsEsophagogastric cancerInduction therapyNonhematologic toxicityPrior therapyDaily radiotherapyLate complicationsOverall survivalSurgical candidatesPhase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).
Tawfik B, Gerber D, Burtness B, Hughes R, Myers L, Sumer B, Truelson J, Strom T, Kurian P, Saleem S, Pearson J, Zhu H, Khan S. Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC). Journal Of Clinical Oncology 2017, 35: tps6098-tps6098. DOI: 10.1200/jco.2017.35.15_suppl.tps6098.Peer-Reviewed Original ResearchAnaplastic thyroid cancerThyroid cancerCell cycle progressionII trialCycle progressionResponse ratePhase I/II trialOpen-label trialRare thyroid cancerPhase II trialAggressive clinical courseCDK 4/6 inhibitorsEffective treatment optionOverall response rateMTOR inhibitor everolimusATC cell linesRapid cell cycle progressionMedian OSATC patientsPrimary endpointSecondary endpointsMetastatic diseaseTrue response rateAdditional patientsClinical course
2006
Postchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast Cancer
Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA. Postchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast Cancer. The Cancer Journal 2006, 12: 212-221. PMID: 16803680, DOI: 10.1097/00130404-200605000-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDocetaxelDoxorubicinFemaleGranulocyte Colony-Stimulating FactorHumansMagnetic Resonance ImagingMastectomyMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm, ResidualPrognosisSurvival RateTaxoidsTreatment OutcomeConceptsAdvanced breast cancerPathologic complete responseMagnetic resonance imagingComplete responseBreast cancerResonance imagingNeoadjuvant chemotherapyPreoperative magnetic resonance imagingResidual invasive carcinomaBreast magnetic resonance imagingResidual tumor sizeSerial magnetic resonanceBreast magnetic resonanceMagnetic resonanceEligible patientsPrimary chemotherapyNeoadjuvant therapyResidual cancerAxillary lesionsPathologic evaluationStable patientsAdditional patientsPosttreatment examinationResidual diseaseTumor size